1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
  4. > Pain Relieving Drugs Market Forecast 2014-2024 : Future Prospects for Leading Companies

Report Details

Pain relieving drugs - new study showing you trends, R&D progress, and predicted revenues
Where is the pain relieving drugs market heading? What are the commercial prospects for this market and related technologies? See what the future holds for painkillers. Visiongain’s new report shows you potential revenues and other trends to 2024, discussing data, opportunities and prospects.

Our 323 page report provides 265 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at world market, submarket and national level. You will see financial results, interviews, trends, opportunities and revenue predictions. Much opportunity remains in this growing pharma market.

Forecasts from 2014-2024 and other analyses show you commercial prospects

Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and STEP), company profiles and commercial developments. Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
- Dr Stephen K Doberstein, Senior Vice President and Chief Scientific Officer, Nektar Therapeutics
- Dr Tom McCarthy, Chief Executive Officer, Spinifex Pharmaceuticals

You find prospects for key submarkets

In addition to analyses of the overall world market, you see revenue forecasts for these six submarkets to 2024:
- Narcotic pain relieving drugs
- Neuropathic pain relieving drugs
- Treatments for arthritis
- Non-Narcotic pain relieving drugs
- Treatments for migraines
- Other pain relieving drugs

Technologies that improve on the tolerance and dependence issues associated with pain relieving drugs will achieve success. The increasing use of abuse-resistant delivery systems in particular will be a major benefiting factor for pain relieving drugs as a whole.

Our investigation shows business research and analyses with individual revenue forecasts and discussions. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for products

How will leading drugs perform to 2024 at the world level? Our study forecasts sales of 28 products including these brands:
- Celebrex
- Voltaren
- Relpax
- Lyrica
- Cymbalta
- Aspirin
- Zomig
- Duragesic
- Oxycontin ER
- Panadol
- Lidoderm

Our study includes OTC (over-the-counter) and Rx (prescription) pain relieving medicines.

Discover how high revenues can go. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

Our analysis also breaks the main world forecast into geographical markets.

What are the prospects for the leading regions and countries?

Developments worldwide will influence the market, especially fast-rising demand in emerging countries. There will be many opportunities for pain-treating products.

In addition to analyses of the overall world market, you discover individual revenue forecasts for 13 national markets to 2024:
- US
- Japan
- Germany
- France
- UK
- Italy
- Spain
- Brazil
- Russia
- India
- China
- Turkey
- South Korea
- Rest of the World

Our analyses show sustained growth, particularly for the BRIC nations of Brazil, Russia, India, and China. New product approvals and the development of abuse-resistant drugs will influence market growth.

Regulatory, demographic, and commercial developments worldwide will influence the mar

Table Of Contents

Pain Relieving Drugs Market Forecast 2014-2024 : Future Prospects for Leading Companies
1. Report Overview
1.1 Global Pain Relieving Drugs: Market Overview
1.2 Global Pain Relieving Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. An Introduction to Pain and Pain Management
2.1 Pain: A Sensory And Emotional Phenomenon
2.1.1 Pain: A Short History
2.1.2 Pain Pathways And The Origin Of Pain
2.2 The World Health Organisation (WHO) Pain Ladder
2.2.1 Classification Of Pain
2.2.1.1 Acute Pain
2.2.1.2 Chronic Pain
2.3 The Psychosocial Effects Of Chronic Pain
2.3.1 Chronic Cancer Pain
2.3.2 Neuropathic Pain
2.3.3 Identifying Neuropathic Pain
2.4 The Neurochemistry Of Pain
2.4.1 Prostaglandins
2.4.2 Opioids
2.5 Pain Management - A Brief Overview
2.6 Pain Management Drugs
2.6.1 The Use Of Opioids In Pain Treatment
2.6.2 OTC Pain Relievers
2.7 Market Definition

3. World Pain Relieving Drugs Market 2014-2024
3.1 Global Pain Relieving Drugs: Market Overview
3.1.1 Categorisation of the Global Pain Relieving Drug Market
3.1.2 Pain Relieving Drugs: A Growing Market
3.2 The Global Pain Relieving Drugs Market in 2013
3.2.1 Market Dominance of Arthritic Pain Relieving Drugs
3.3 Global Pain Relieving Drugs: Market Forecast 2014-2024
3.3.1 Market Sectors That Will Drive Growth
3.3.2 Abuse Deterrents and Safety Measures Will Boost Narcotic Pain Relieving Drugs Market Growth
3.3.3 Changing Market Shares by Sector 2014-2024

4. Narcotic Pain Relieving Drugs: World Market Analysis and Forecast 2014-2024
4.1 The Global Narcotic Pain Relieving Drugs Market in 2013
4.1.1 Global Narcotic Pain Relieving Drugs: Market Forecast 2014-2024
4.1.2 Changing Market Shares By Leading Drugs 2014-2024
4.2 Opana ER (Endo Pharmaceuticals): Market Analysis
4.2.1 Tamper-Proof Opana ER Products
4.2.2 Opana ER: Historical Sales Analysis, 2014-2024
4.2.3 Opana ER: Sales Forecast 2014-2024
4.3 Duragesic: Market Analysis
4.3.1 Duragesic: Historical Sales Analysis, 2011-2013
4.3.2 Duragesic: Sales Forecast 2014-2024
4.4 Oxycontin ER: Market Analysis
4.4.1 Tamper Resistant Oxycontin ER
4.4.2 Oxycontin ER: Patent Expiries and Legal Battles
4.4.3 Oxycontin ER: Sales Forecast 2014-2024
4.5 Ultram: Market Analysis
4.5.1 Ultram: Sales Forecast 2014-2024
4.6 Zaldiar/Ixprim: Market Analysis
4.6.1 Zaldiar/Ixprim: Historical Sales Analysis, 2011-2013
4.6.2 Zaldiar/Ixprim: Sales Forecast 2014-2024
4.7 Other Narcotic Pain Relieving Drugs
4.7.1 Subsys (Insys Therapeutics)
4.7.2 Oxecta (Pfizer)
4.7.3 Other Narcotic Pain Relieving Drugs: Sales Forecast 2014-2024

5. Non-Narcotic Pain Relieving Drugs: World Market Analysis and Forecast 2014-2024
5.1 The Global Non-Narcotic Pain Relieving Drugs Market in 2013
5.1.1 Global Non-Narcotic Pain Relieving Drugs: Market Forecast 2014-2024
5.1.2 Changing Market Shares By Leading Drugs 2014-2024
5.2 Aspirin (Bayer): Market Analysis
5.2.1 Aspirin (Bayer): Historical Sales Analysis, 2010-2013
5.2.2 Aspirin (Bayer): Sales Forecast 2014-2024
5.3 Panadol: Market Analysis
5.3.1 Panadol: Historical Sales Analysis, 2008-2013
5.3.2 Panadol: Sales Forecast 2014-2024
5.4 Advil: Market Analysis
5.4.1 Advil: Historical Sales Analysis, 2012 and 2013
5.4.2 Advil: Sales Forecast 2014-2024
5.5 Tylenol: Market Analysis
5.5.1 Tylenol: Sales Forecast 2014-2024
5.6 Other Non-Narcotic Pain Drugs
5.6.1 Exparel (Pacira Pharmaceuticals)
5.6.2 Other Non-Narcotic Pain Drugs: Sales Forecast 2014-2024

6. Neuropathic Pain Relieving Drugs: World Market Analysis and Forecast 2014-2024
6.1 An Introduction to Neuropathic Pain
6.1.1 Identifying Neuropathic Pain
6.1.2 Pharmacological Interventions for Neuropathic Pain
6.1.2.1 Analgesics in Neuropathic Pain
6.1.2.2 Anti-Convulsants
6.1.2.3 Local Anaesthetics
6.1.2.4 Anti-Depressants
6.1.2.5 Aldose Reductase Inhibitors
6.1.3 The Global Neuropathic Pain Relieving Drugs Market in 2013
6.1.4 Global Neuropathic Pain Relieving Drugs: Market Forecast 2014-2024
6.1.5 Changing Market Shares By Leading Drugs 2014-2024
6.2 Lidoderm: Market Analysis
6.2.1 Lidoderm Patent Expiry and Endo Pharma - Watson/Actavis Agreement
6.2.2 Lidoderm Marketing Probe
6.2.3 Lidoderm: Historical Sales Analysis, 2009-2013
6.2.4 Lidoderm: Sales Forecast 2014-2024
6.3 Lyrica: Market Analysis
6.3.1 Lyrica: Historical Sales Analysis, 2009-2013
6.3.2 Lyrica: Sales Forecast 2014-2024
6.4 Cymbalta: Market Analysis
6.4.1 Cymbalta: Historical Sales Analysis, 2008-2013
6.4.2 Cymbalta: Sales Forecast 2014-2024
6.5 Neurontin: Market Analysis
6.5.1 Neurontin: Historical Sales Analysis, 2009-2013
6.5.2 Neurontin: Sales Forecast 2014-2024
6.6 Nucynta: Market Analysis
6.6.1 Nucynta: Historical Sales Analysis, 2011-2013
6.6.2 Nucynta: Sales Forecast 2014-2024
6.7 Other Neuropathic Pain Relieving Drugs
6.7.1 Retigabine (GSK; Valeant)
6.7.2 Other Neuropathic Pain Relieving Drugs: Sales Forecast 2014-2024

7. Anti-Migraine Drugs: World Market Analysis and Forecast 2014-2024
7.1 Migraine: An Introduction
7.1.1 Management of Migraine
7.1.2 Drugs Being Used In the Treatment of Migraine
7.1.3 Other Migraine Relieving Techniques
7.1.4 The Global Anti-Migraine Pain Relieving Drugs Market in 2013
7.1.5 Global Anti-Migraine Pain Relieving Drugs: Market Forecast 2014-2024
7.1.6 Changing Market Shares By Leading Drugs 2014-2024
7.2 Relpax: Market Analysis
7.2.1 Relpax: Historical Sales Analysis, 2009-2013
7.2.2 Relpax: Sales Forecast 2014-2024
7.3 Maxalt: Market Analysis
7.3.1 Maxalt: Historical Sales Analysis, 2008-2013
7.3.2 Maxalt: Sales Forecast 2014-2024
7.4 Imitrex/Imigran: Market Analysis
7.4.1 Imitrex/Imigran: Historical Sales Analysis, 2008-2013
7.4.2 Imitrex/Imigran: Sales Forecast 2014-2024
7.5 Zomig: Market Analysis
7.5.1 Zomig: Licensing Transfers and Exclusivity
7.5.2 Zomig: Historical Sales Analysis, 2009-2013
7.5.3 Zomig: Sales Forecast 2014-2024
7.6 Botox (Allergan): Market Analysis
7.6.1 Botox: Historical Sales Analysis, 2009-2013
7.6.2 Botox: Sales Forecast 2014-2024
7.7 Treximet: Market Analysis
7.7.1 Treximet: Agreements Between GSK, Pozen Pharmaceuticals and Pernix Therapeutics
7.7.2 The Generic Treats to Treximet
7.7.3 Treximet: Historical Sales Analysis, 2008-2013
7.7.4 Treximet: Sales Forecast 2014-2024
7.8 Axert: Market Analysis
7.8.1 Axert: Historical Sales Analysis, 2011-2013
7.8.2 Axert: Sales Forecast 2014-2024
7.9 Other Anti-Migraine Pain Relieving Drugs: Sales Forecast, 2014-2024
7.10 Anti-Migraine Pain Relieving Drugs Market - Future Prospects
7.10.1 Unmet Needs in the Treatment of Migraine

8. Anti-Arthritic Pain Drugs: World Market Analysis and Forecast 2014-2024
8.1 Understanding Arthritis: An Introduction to its Aetiology and Prevalence
8.1.1 Management of Arthritic Conditions
8.1.2 Drugs Being Used In The Treatment Of Arthritis
8.1.2.1 Analgesics As Pain Relieving Drugs
8.1.2.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
8.1.2.3 Corticosteroids
8.1.2.4 Disease Modifying Anti-Rheumatic Drugs (DMARDS)
8.1.3 Biological Drugs in the Treatment Of Arthritis
8.1.3.1 Biologics Used for Rheumatoid Arthritis
8.1.3.2 The Potential Side Effects of Biologics in the Treatment of Arthritis
8.1.4 The Global Anti-Arthritis Pain Relieving Drugs Market in 2013
8.1.5 Global Anti-Arthritis Pain Relieving Drugs: Market Forecast 2014-2024
8.1.6 Changing Market Shares By Leading Drugs, 2014-2024
8.2 Humira: Market Analysis
8.2.1 Humira: Historical Sales Analysis, 2011-2013
8.2.2 Humira: Sales Forecast 2014-2024
8.3 Enbrel: Market Analysis
8.3.1 Enbrel: Co-Promotions and Marketing Rights
8.3.2 Enbrel: Historical Sales Analysis, 2008-2013
8.3.3 Enbrel: Patent Expiries and Potential Competition, 2014-2024
8.3.4 Enbrel: Sales Forecast 2014-2024
8.4 Remicade: Market Analysis
8.4.1 Remicade: Historical Sales Analysis, 2008-2013
8.4.2 Remicade: Patent Expiries and Potential Competition, 2014-2024
8.4.3 Remicade: Sales Forecast 2014-2024
8.5 Voltaren: Market Analysis
8.5.1 Voltaren: Historical Sales Analysis, 2008-2013
8.5.2 Voltaren: Sales Forecast 2014-2024
8.6 Rituxan (Rituximab, MabThera): Market Analysis
8.6.1 Rituxan: Historical Sales Analysis, 2008-2013
8.6.2 Rituxan: Patent Expiries and Potential Competition, 2014-2024
8.6.3 Rituxan: Sales Forecast 2014-2024
8.7 Celebrex: Market Analysis
8.7.1 Celebrex: Historical Sales Analysis, 2008-2013
8.7.2 Celebrex: Patents, Exclusivity, and Competition, 2014-2024
8.7.3 Celebrex: Sales Forecast 2014-2024
8.8 Arcoxia: Market Analysis
8.8.1 Arcoxia: Historical Sales Analysis, 2008-2013
8.8.2 Arcoxia: Sales Forecast 2014-2024
8.9 Other Anti-Arthritis Pain Relieving Drugs
8.9.1 Duexa (Horizon Pharma)
8.9.2 Lodotra/RAYOS (Horizon Pharma; SkyePharma)
8.9.3 Ofatumumab (Genmab, GSK)
8.9.4 Other Anti-Arthritis Pain Relieving Drugs: Sales Forecast 2014-2024
8.10 Anti-Arthritic Pain Relieving Drug Market - Future Prospects

9. Leading National Markets for Pain Relieving Drugs 2014-2024
9.1 The Pain Relieving Drug Market By Region
9.1.1 The Global Distribution of Pain Relieving Drugs In 2013
9.2 Leading National Markets: Forecast, 2014-2024
9.2.1 Changing Market Shares By Region, 2014-2024
9.3 Regional Pain Relieving Drugs Markets: Analysis and Forecasts, 2014-2024
9.4 United States: The Largest Pain Relieving Drug Market
9.5 The EU5 Markets
9.5.1 EU5 Markets: Changing Market Shares by Country, 2014-2024
9.5.2 Germany
9.5.3 UK
9.5.4 France
9.5.5 Italy
9.5.6 Spain
9.6 Japan
9.7 China
9.8 South Korea
9.9 Brazil
9.10 India
9.11 Russia
9.12 Turkey
9.13 Rest of the World

10. Pain Relieving Drugs: RandD Pipeline 2014-2024
10.1 Innovative Products Currently In Development Will Drive Growth
10.1.1 Large Developmental Pipelines Encouraged By High Potential Growth
10.2 Development Pipeline For Narcotic Pain Relieving Drugs, 2014
10.2.1 Remoxy (Durect, Pain Therapeutics, Pfizer)
10.2.2 MoxDuo IR (Shire; China Aoxing; QRxPharma)
10.2.3 ALO-02 (Pfizer)
10.2.4 DETERx - COL-003 (Collegium Pharmaceuticals)
10.2.5 Acurox (Acura; Pfizer)
10.2.6 Morphine-6-Glucuronide (Paion)
10.2.7 Acuracet (Acura)
10.2.8 ARX-02 (AcelRx Pharmaceuticals)
10.2.9 Zohydro ER (Zogenix)
10.2.10 BEMA Buprenorphine (BioDelivery Sciences; Endo Pharmaceuticals)
10.3 Development Pipeline For Non-Narcotic Pain Relieving Drugs, 2014
10.3.1 Lofexidine Hydrochloride (US World Meds)
10.3.2 Synera (Nuvo Research)
10.3.3 Neosaxitoxin (Proteus SA; Boston Children Hospital)
10.3.4 OMS103 (Omeros)
10.3.5 Tetrodotoxin (CK Life Sciences; WEX Pharmaceuticals)
10.4 Development Pipeline For Neuropathic Pain Relieving Drugs, 2014
10.4.1 Perampanel (Eisai)
10.4.2 Serenbotase (Syntaxin, Ipsen, Allergan)
10.4.3 EMA401 (Spinifex Pharmaceuticals)
10.4.4 Ralfinamide (Newron)
10.4.5 NT-11624 (Neurotune)
10.4.6 AmiKet (Immune Pharmaceuticals)
10.4.7 Eladur (Durect; Impax Laboratories)
10.4.8 Clonidine Gel (Arcion Therapeutics; BioDelivery Sciences)
10.4.9 AVP-923 (Avanir Pharmaceuticals)
10.4.10 ARC-2022 (Arcion Therapeutics)
10.5 Development Pipeline For Anti-Migraine Pain Relieving Drugs, 2014
10.5.1 Zecuity (NuPathe; Teva)
10.5.2 Lasmiditan (CoLucid Pharmaceuticals)
10.5.3 NXN-188 (NeurAxon)
10.5.4 Levadex/Semprana (Allergan)
10.6 Development Pipeline For Anti-Arthritis Pain Relieving Drugs, 2014
10.6.1 Zavryl/Ibuprofen-PC (PLx Pharma)
10.6.2 Naproxcinod (NicOx)
10.6.3 Xeljanz (Pfizer)
10.6.4 Masitinib (AB Science)
10.6.5 Belimumab (GSK, Human Genome Sciences)
10.7 What Does the Future Hold for Pain Relieving Drugs Research and Development?
10.8 Solubility: A Hindrance To Drug Development
10.9 Monoclonal Antibodies (MAbs) - Potential Novel Pain Drugs Facing Challenges
10.10 New Opioids Providing Opportunities For Growth
10.11 The Potential Use Of Cannabinoids In Pain Relief

11. Qualitative Analysis for the Global Pain Relieving Drugs Market 2014-2024
11.1 Market Factors Influencing The Pain Relieving Drugs Market
11.2 SWOT Analysis Of The Pain Relieving Drugs Market, 2014-2024
11.2.1 Strengths
11.2.1.1 Cost Effectiveness: A Major Driver for Growth
11.2.1.2 Promising Candidates In The RandD Pipeline
11.2.2 Weaknesses
11.2.2.1 Product Withdrawals And Slow Regulatory Approvals
11.2.2.2 Concerns Over Drug Side Effects
11.2.2.3 Education In Pain Management Is A Key Unmet Need
11.2.3 Opportunities
11.2.3.1 Reformulations Of Existing Drugs Will Drive Market Growth
11.2.3.2 Reforms In Narcotics Offer Growth Opportunities
11.2.3.3 Ageing Population - Growth Driver For Pain Relieving Drugs
11.2.3.4 The Economic Benefits Of Expansion Into Emerging Markets
11.2.3.5 OTC Switching May Help To Delay Generic Erosion
11.2.4 Threats
11.2.4.1 Patent Expiries Will Lead To Generic Competition
11.2.4.2 Regulatory And Pricing Scrutiny Could Suffocate Market Growth
11.2.4.3 Inadequate Reimbursement Levels: A Potential Restraint On Market Growth
11.3 STEP Analysis Of The Pain Relieving Drugs Market, 2014-2024
11.3.1 Social Factors Affecting The Pain Relieving Drugs Market
11.3.2 Technological Factors Affecting the Pain Relieving Drugs Market
11.3.3 Economic Factors Affecting The Pain Relieving Drugs Market
11.3.4 Political Factors Affecting The Pain Relieving Drugs Market

12. Expert Opinions
12.1 Interview With Dr Stephen K Doberstein, Senior Vice President And Chief Scientific Officer, Nektar Therapeutics
12.1.1 Pain Relieving Drugs: Current Trends In The Market
12.1.2 Nektar's NKTR-181 Product And Its Mechanism To Mitigate Against Opioid Abuse
12.1.3 Key Developments In Pain Management And The Steps Being Taken To Reduce Addiction To Pain Drugs
12.1.4 Nektar's Development Programme And Issues Around Penetration Of The Blood-Brain Barrier
12.1.5 Future Expansion Plans
12.1.6 On The Unmet Need For Abuse-Resistant And Highly Efficacious Pain Relieving Drugs
12.1.7 On The Developments Expected To Enter The Market In The Coming Years And The Need To Re-invent Known Classes Of Analgesic Molecules
12.2 Interview With Dr Tom McCarthy, Chief Executive Officer, Spinifex Pharmaceuticals
12.2.1 The Quest For Alternative Pain Relief Therapies
12.2.2 The Future Potential Of Combination Therapies In Pain Relief
12.2.3 On Developing, Validating and Demonstrating The Clinical Potential Of Novel Mechanisms For Tackling Pain
12.2.4 On The Market Potential Of Spinifex's EMA401 Product
12.2.5 On Expansion Plans For EMA401 And Pain Relief As A Whole
12.2.6 The Drug Development And Commercialisation Challenges Facing The Pain Relieving Drugs Market
12.2.7 Future Outlook On The Market And The Potential For Novel Analgesics

13. Conclusions
13.1 Market Overview
13.2 The Likely Impacts Of Patent And Exclusivity Expiries On Pain Relieving Drugs
13.3 Major Growth Drivers For Pain Relieving Drugs
13.4 Under-Served Needs In Neuropathic Pain Leaves Room For Growth
13.5 The Narcotic Pain Relieving Drugs Market: Its Driving And Restraining Factors
13.6 Botox Approval Expected To Boost Anti-Migraine Submarket
13.7 The Rise Of Biological Anti-Arthritic Pain Drugs
13.8 Emerging Markets Set To Drive Steer Market Forward
13.9 What Does The Future Hold For Pain Relieving Drugs?

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Migraine  - Market Insights, Epidemiology and Market Forecast-2023

Migraine  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Migraine - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...

Global and Chinese Pain Relieving Drug Industry, 2016 Market Research Report

Global and Chinese Pain Relieving Drug Industry, 2016 Market Research Report

  • $ 3000
  • Industry report
  • November 2016
  • by Prof Research

The ’Global and Chinese Pain Relieving Drug Industry, 2011-2021 Market Research Report’ is a professional and in-depth study on the current state of the global Pain Relieving Drug industry with a focus ...

Global Antipyrine Market Research Report 2016

Global Antipyrine Market Research Report 2016

  • $ 2850
  • Industry report
  • October 2016
  • by 9Dimen Research

2016 Global Antipyrine Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Antipyrine industry, focusing on the main regions (North America, ...


Download Unlimited Documents from Trusted Public Sources

Pain Relief Industry in the US

  • November 2016
    31 pages
  • Pain Relief  

    Stroke  

  • United States  

View report >

OTC Industry in the US

  • November 2016
    52 pages
  • United States  

View report >

OTC Markets in the US

  • October 2016
    6 pages
  • OTC  

  • United States  

View report >

Otc Markets In The Us

2 months ago

Global Otc Industry

2 months ago

Otc Industry In The Us

2 months ago

Related Market Segments :

Pain Relief

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.